True Bearing Diagnostics

True Bearing Diagnostics is a private U.S. precision diagnostics company developing RNA-based blood tests for earlier and less invasive disease detection. Its lead product, TruCAD, is designed to support early detection of coronary artery disease using blood RNA biomarkers as an alternative to more invasive and expensive diagnostic workups. The company is also developing TruNAV and related biomarker panels for infection detection, including bacterial, viral, and biofilm-associated infections such as pneumonia and appendicitis. True Bearing was founded to commercialize research originating from the St. Laurent Institute and George Washington University. Based on available company-profile sources, it appears to be an early-stage revenue-generating diagnostics company rather than a therapeutics developer.